Tiger Brokers

Praxis Precision Medicines Says FDA Extends Review of Relutrigine Application

Dow Jones
Jun 30

Praxis Precision Medicines said Monday the Food and Drug Administration extended its review of the company's application for relutrigine, an epilepsy treatment, delaying a decision by three months.

The FDA set a new target decision date of Dec. 27, 2026, from Sept. 27, after the company submitted additional sensitivity analyses of existing clinical trial data that the agency classified as a major amendment.

Praxis said the FDA didn't request any new clinical studies and didn't identify any safety or manufacturing concerns. The company said it continues to work with the agency as the review remains ongoing.

Relutrigine is being reviewed as a treatment for rare forms of childhood epilepsy caused by SCN2A and SCN8A gene mutations.

Write to Anvee Bhutani at anvee.bhutani@wsj.com

(END) Dow Jones Newswires

June 29, 2026 16:57 ET (20:57 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10